# Alnylam Pharmaceuticals share price today (Alnylam Pharmaceuticals, Inc., ALNY)

> Alnylam Pharmaceuticals, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. ALNY · Healthcare · Biotechnology · data as of 5 November 2026. Page: https://www.sectoralpha.in/us/stocks/alny

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $156.51 (−64.6% in a year)
- P/E: 8.1×, over 1 year
- Revenue (Jun 2026): $1.3 B (+66.9% on a year ago)
- Profit (Jun 2026): $164 M
- Operating margin: 17.9% (+20.0 points on a year ago)
- ROE: 40%, FY25

Biggest thing to watch: margins are the best this company has ever reported. Every ratio looks better at a record, so the story depends on margins staying high. ## What is the Alnylam Pharmaceuticals share price today? Alnylam Pharmaceuticals, Inc.'s share price was $156.51 at the close on 5 November 2026. It has been falling for 17 weeks. That is 44.4% below its average price over the last 200 trading days. In the last 52 weeks it traded between $157 and $458, and at that close it was at the low of that range. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 53 weeks running. Over the last 10 years the share price moved +152% while the S&P 500 moved +245%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 31 October 2025. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Alnylam Pharmaceuticals pay? Alnylam Pharmaceuticals, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Alnylam Pharmaceuticals on? Alnylam Pharmaceuticals is on one of our US lists: Nasdaq 100 companies. [Nasdaq 100 companies](https://www.sectoralpha.in/nasdaq-100-stocks)

## Is Alnylam Pharmaceuticals profitable? Alnylam Pharmaceuticals, Inc. earned $164 M of net profit in the Jun 2026 quarter. Full-year FY25 profit was $314 M. That is 12.7% of the quarter's revenue. The same quarter a year earlier lost $72.2 M. 7 of the last 12 reported quarters were loss-making. ## How much revenue does Alnylam Pharmaceuticals make, and is it growing? Alnylam Pharmaceuticals, Inc. reported $1.3 B of revenue in the Jun 2026 quarter, +66.9% on the same quarter a year earlier. That is the 7th quarter in a row with growth on the year before. Over 4 years it has grown 44.8% a year on average. The last full year, FY25, came in at $3.7 B. The last four reported quarters add to $4.8 B. FY25 revenue was $3.7 B, +65.2% on the year before. Recent pace: the last four quarters grew +99.4% on average, against 44.8% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +95.1%, against +43.2% a year over the last 8 quarters (accelerating). ## How much of every $100 of sales does Alnylam Pharmaceuticals keep? Alnylam Pharmaceuticals, Inc.'s operating margin was 17.9% in the Jun 2026 quarter, 20.0 percentage points higher than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 5 years it has been between −83.9% and 13.5%. The latest quarter is above every full year in that period. Across 5 years it has been between −83.9% and 13.5%, and FY25's 13.5% is the highest of them. Why the margin moved: operating margin changed +20.0 percentage points on the year while gross margin changed −4.6 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. When margins are at a record, every ratio built on profit looks better than usual, so watch whether they hold. ## Is Alnylam Pharmaceuticals' profit turning into cash? Alnylam Pharmaceuticals, Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 it brought in $524 M of operating cash against $314 M of profit. After $58.7 M of spending on assets, $465 M was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Alnylam Pharmaceuticals' cash go? Alnylam Pharmaceuticals, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $155 M on assets over the last 3 years. Averaged over those years that is 1.4% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $155 M over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Alnylam Pharmaceuticals' P/E ratio, and how does it compare with its own history? Alnylam Pharmaceuticals, Inc.'s P/E is 8.1×, with too little history to compare. This compares the share price with the company’s own past. It does not say what the business is worth. In short: there is too little history to say whether the multiple is high or low for this company, so the earnings trend underneath matters more than the multiple. ## Is the Alnylam Pharmaceuticals business getting better or worse? Alnylam Pharmaceuticals, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Alnylam Pharmaceuticals earn on its capital? Alnylam Pharmaceuticals, Inc. earned a ROE of 40% in FY25. That is up from a low of −415% in FY24. Its return on capital used (ROIC) is 41.5 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 8.4% net margin and 0.75× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 8.4% net margin × 0.75× asset turnover × 6.29× leverage (assets divided by equity) ≈ 39.6% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 48.3% − 6.8% = +41.5 percentage points. The 6.8% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. A gap this wide means each dollar put back into the business creates more than a dollar of value. The 48.3% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at 100.9%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Alnylam Pharmaceuticals have too much debt? Alnylam Pharmaceuticals, Inc. has total debt of $3.0 B against shareholder equity of $1.4 B as of Jun 2026, so its debt is 2.21× its equity. Year by year, that ratio went from 3.72 in FY21 to 3.76 in FY25. Keep that borrowing in mind when reading the returns on this page. ## What is the Alnylam Pharmaceuticals shareholding pattern? 4.9% of Alnylam Pharmaceuticals, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 5.0 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Alnylam Pharmaceuticals from balance-sheet trouble? For Alnylam Pharmaceuticals, Inc., the Z-score is 6.83. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 6.83 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does Alnylam Pharmaceuticals rank in its industry? 51.6 out of 100, rank 14 of 30 in Biotechnology, with 64% of the evidence available. Alnylam Pharmaceuticals, Inc. scores 51.6 out of 100 against the 30 companies it is compared with in Biotechnology, ranking 14. Earnings are strong; relative strength in its sector is -60.8% and the one-year return is -64.6%. The four parts add up to the total exactly: 24.2 + 16.7 + 9 + 1.7 = 51.6. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Alnylam Pharmaceuticals compared with? Alnylam Pharmaceuticals ranks 14 of 30 Biotechnology companies on the 4-Factor Sector Score, with 51.6 out of 100. 1. [Exelixis, Inc.](https://www.sectoralpha.in/us/stocks/exel) EXEL · breaking out · Most evidence points up · 81% evidence 76.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.7/35 · Revenue 9.3% · Profit 42.8% · Operating margin change 1.9 points · 83% evidence Capital efficiency 20.9/25 · ROCE 46.5% · Operating margin 39.5% · 76% evidence Valuation 14.6/20 · P/E 15.9× · PEG 0.3 · 65% evidence Relative strength 17.9/20 · Lead over its industry 9.7% · Lead over S&P 500 35.4% · 1 year 68.4% · 100% evidence · 8 of 12 weeks ahead Exact sum: 22.7 + 20.9 + 14.6 + 17.9 = 76.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 2. [Halozyme Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/halo) HALO · leader · Most evidence points up · 81% evidence 72.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.7/35 · Revenue 41.1% · Profit -25.9% · Operating margin change -2.4 points · 83% evidence Capital efficiency 20.9/25 · ROCE 42.3% · Operating margin 59.8% · 76% evidence Valuation 14.6/20 · P/E 22.4× · PEG 0.25 · 65% evidence Relative strength 18.8/20 · Lead over its industry 21.7% · Lead over S&P 500 48.8% · 1 year 80.2% · 100% evidence · 12 of 12 weeks ahead Exact sum: 17.7 + 20.9 + 14.6 + 18.8 = 72 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [Incyte Corporation](https://www.sectoralpha.in/us/stocks/incy) INCY · turning · Most evidence points up · 71% evidence 65.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 27.1/35 · Revenue 26.9% · Profit 85.3% · Operating margin change 16.3 points · 83% evidence Capital efficiency 20.5/25 · ROCE 28.1% · Operating margin 41.9% · 76% evidence Valuation 10.9/20 · P/E 14× · PEG n/a · 15% evidence Relative strength 7.2/20 · Lead over its industry -12.7% · Lead over S&P 500 8.2% · 1 year 11.4% · 100% evidence · 5 of 12 weeks ahead Exact sum: 27.1 + 20.5 + 10.9 + 7.2 = 65.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Genmab A/S](https://www.sectoralpha.in/us/stocks/gmab) GMAB · leader · Evidence leans up · 81% evidence 61.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 11.0/35 · Revenue 18.2% · Profit -39.3% · Operating margin change -3.7 points · 83% evidence Capital efficiency 15.6/25 · ROCE 11.7% · Operating margin 35.2% · 76% evidence Valuation 15.1/20 · P/E 21.4× · PEG 0.21 · 65% evidence Relative strength 19.5/20 · Lead over its industry 33.6% · Lead over S&P 500 65.2% · 1 year 83.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 11 + 15.6 + 15.1 + 19.5 = 61.2 · What this means: Relative strength against the index is 65.2%, and revenue and profit growth are weak. 5. [argenx SE](https://www.sectoralpha.in/us/stocks/argx) ARGX · turning · Evidence leans up · 85% evidence 60.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.9/35 · Revenue 60.6% · Profit 22.4% · Operating margin change 5.9 points · 95% evidence Capital efficiency 17.1/25 · ROCE 18.9% · Operating margin 36.3% · 76% evidence Valuation 10.4/20 · P/E 32× · PEG 1.39 · 65% evidence Relative strength 8.4/20 · Lead over its industry -17.4% · Lead over S&P 500 2.7% · 1 year 4.7% · 100% evidence · 6 of 12 weeks ahead Exact sum: 24.9 + 17.1 + 10.4 + 8.4 = 60.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [BeOne Medicines AG](https://www.sectoralpha.in/us/stocks/onc) ONC · leader · Evidence leans up · 64% evidence 57.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.0/35 · Revenue 34.3% · Profit n/a · Operating margin change 12.4 points · 62% evidence Capital efficiency 13.3/25 · ROCE 13.1% · Operating margin 19.1% · 76% evidence Valuation 9.1/20 · P/E 48.3× · PEG n/a · 15% evidence Relative strength 12.2/20 · Lead over its industry -6.3% · Lead over S&P 500 16.5% · 1 year 21.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 23 + 13.3 + 9.1 + 12.2 = 57.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Kymera Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/kymr) KYMR · turning · Evidence leans up · 61% evidence 57.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.9/35 · Revenue 100% · Profit n/a · Operating margin change 620.5 points · 62% evidence Capital efficiency 6.8/25 · ROCE -22% · Operating margin -116.3% · 76% evidence Valuation 10.0/20 · P/E n/a · PEG n/a · 0% evidence Relative strength 16.9/20 · Lead over its industry 11% · Lead over S&P 500 36.2% · 1 year 118.4% · 100% evidence · 7 of 12 weeks ahead Exact sum: 23.9 + 6.8 + 10 + 16.9 = 57.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Spyre Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/syre) SYRE · quiet · Too little evidence to rank firmly · 56% evidence 56.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.6/35 · Revenue n/a · Profit n/a · Operating margin change 999.3 points · 52% evidence Capital efficiency 8.6/25 · ROCE -24.5% · Operating margin n/a · 61% evidence Valuation 11.0/20 · P/E -8.2× · PEG n/a · 15% evidence Relative strength 12.9/20 · Lead over its industry 21.2% · Lead over S&P 500 46.6% · 1 year 328.9% · 100% evidence · 4 of 12 weeks ahead Exact sum: 23.6 + 8.6 + 11 + 12.9 = 56.1 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 9. [Moderna, Inc.](https://www.sectoralpha.in/us/stocks/mrna) MRNA · leader · Evidence leans up · 64% evidence 55.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.4/35 · Revenue -27.6% · Profit n/a · Operating margin change 80.8 points · 62% evidence Capital efficiency 6.5/25 · ROCE -28.9% · Operating margin -557.9% · 76% evidence Valuation 11.2/20 · P/E -11.6× · PEG n/a · 15% evidence Relative strength 20.0/20 · Lead over its industry 161.6% · Lead over S&P 500 205.6% · 1 year 882.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 17.4 + 6.5 + 11.2 + 20 = 55.1 · What this means: Relative strength against the index is 205.6%, and revenue and profit growth are weak. 10. [Krystal Biotech, Inc.](https://www.sectoralpha.in/us/stocks/krys) KRYS · quiet · Evidence leans up · 81% evidence 55.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.4/35 · Revenue 22.6% · Profit 65.1% · Operating margin change 8 points · 83% evidence Capital efficiency 16.1/25 · ROCE 14.4% · Operating margin 49% · 76% evidence Valuation 12.4/20 · P/E 45.4× · PEG 0.77 · 65% evidence Relative strength 4.1/20 · Lead over its industry -19% · Lead over S&P 500 0.1% · 1 year 51.7% · 100% evidence · 4 of 12 weeks ahead Exact sum: 22.4 + 16.1 + 12.4 + 4.1 = 55 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. [Jazz Pharmaceuticals plc](https://www.sectoralpha.in/us/stocks/jazz) JAZZ · quiet · Evidence leans up · 74% evidence 55.0 out of 100 Growth Capital Valuation Relative
12. [Royalty Pharma plc](https://www.sectoralpha.in/us/stocks/rprx) RPRX · turning · Evidence leans up · 81% evidence 53.7 out of 100 Growth Capital Valuation Relative
13. [Regeneron Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/regn) REGN · leader · Evidence leans up · 81% evidence 52.8 out of 100 Growth Capital Valuation Relative
14. Alnylam Pharmaceuticals, Inc. this page ALNY · basing · Evidence leans up · 64% evidence 51.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.2/35 · Revenue 95.1% · Profit n/a · Operating margin change 20 points · 62% evidence Capital efficiency 16.7/25 · ROCE 24.7% · Operating margin 17.9% · 76% evidence Valuation 9.0/20 · P/E 49.7× · PEG n/a · 15% evidence Relative strength 1.7/20 · Lead over its industry -60.8% · Lead over S&P 500 -50.1% · 1 year -64.6% · 100% evidence · 0 of 12 weeks ahead Exact sum: 24.2 + 16.7 + 9 + 1.7 = 51.6 · What this means: Earnings are strong; relative strength in its sector is -60.8% and the one-year return is -64.6%. 15. [Protagonist Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/ptgx) PTGX · losing its lead · Evidence leans down · 74% evidence 49.6 out of 100 Growth Capital Valuation Relative
16. [Vertex Pharmaceuticals Incorporated](https://www.sectoralpha.in/us/stocks/vrtx) VRTX · breaking out · Evidence leans down · 85% evidence 46.9 out of 100 Growth Capital Valuation Relative
17. [Bio-Techne Corporation](https://www.sectoralpha.in/us/stocks/tech) TECH · turning · Evidence leans down · 74% evidence 44.4 out of 100 Growth Capital Valuation Relative
18. [Roivant Sciences Ltd.](https://www.sectoralpha.in/us/stocks/roiv) ROIV · turning · Too little evidence to rank firmly · 60% evidence 39.5 out of 100 Growth Capital Valuation Relative
19. [Summit Therapeutics Inc.](https://www.sectoralpha.in/us/stocks/smmt) SMMT · breaking out · Too little evidence to rank firmly · 53% evidence 39.2 out of 100 Growth Capital Valuation Relative
20. [Revolution Medicines, Inc.](https://www.sectoralpha.in/us/stocks/rvmd) RVMD · quiet · Too little evidence to rank firmly · 53% evidence 38.7 out of 100 Growth Capital Valuation Relative
21. [Madrigal Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/mdgl) MDGL · quiet · Evidence leans down · 61% evidence 37.2 out of 100 Growth Capital Valuation Relative
22. [Insmed Incorporated](https://www.sectoralpha.in/us/stocks/insm) INSM · basing · Evidence leans down · 61% evidence 35.2 out of 100 Growth Capital Valuation Relative
23. [BridgeBio Pharma, Inc.](https://www.sectoralpha.in/us/stocks/bbio) BBIO · quiet · Evidence leans down · 61% evidence 35.2 out of 100 Growth Capital Valuation Relative
24. [BioNTech SE](https://www.sectoralpha.in/us/stocks/bntx) BNTX · quiet · Most evidence points down · 64% evidence 33.1 out of 100 Growth Capital Valuation Relative
25. [BioMarin Pharmaceutical Inc.](https://www.sectoralpha.in/us/stocks/bmrn) BMRN · quiet · Most evidence points down · 81% evidence 26.8 out of 100 Growth Capital Valuation Relative
26. [Ascendis Pharma A/S](https://www.sectoralpha.in/us/stocks/asnd) ASND · turning · Too little evidence to rank firmly · 44% evidence 63.3 out of 100 Growth Capital Valuation Relative
27. Apogee Therapeutics, Inc. APGE · Too little evidence to rank firmly · 27% evidence 47.2 out of 100 Growth Capital Valuation Relative
28. Nuvalent, Inc. NUVL · Too little evidence to rank firmly · 20% evidence 41.2 out of 100 Growth Capital Valuation Relative
29. [Crinetics Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/crnx) CRNX · Too little evidence to rank firmly · 35% evidence 38.0 out of 100 Growth Capital Valuation Relative
30. Vaxcyte, Inc. PCVX · breaking out · Too little evidence to rank firmly · 47% evidence 37.4 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Biotechnology](https://www.sectoralpha.in/us/sectors/biotechnology), all 30 compared on one page. ## Which companies are close to Alnylam Pharmaceuticals in size? Alnylam Pharmaceuticals is the 13th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: Incyte Corporation, Insmed Incorporated and BioNTech SE. Just below it: Exelixis, Inc., Ascendis Pharma A/S and Jazz Pharmaceuticals plc. ### Biotechnology companies close in size

1. [Incyte Corporation](https://www.sectoralpha.in/us/stocks/incy) $24.1 billion
2. [Insmed Incorporated](https://www.sectoralpha.in/us/stocks/insm) $23.9 billion
3. [BioNTech SE](https://www.sectoralpha.in/us/stocks/bntx) $21.3 billion
4. Alnylam Pharmaceuticals, Inc. $21 billion
5. [Exelixis, Inc.](https://www.sectoralpha.in/us/stocks/exel) $16.8 billion
6. [Ascendis Pharma A/S](https://www.sectoralpha.in/us/stocks/asnd) $16.6 billion
7. [Jazz Pharmaceuticals plc](https://www.sectoralpha.in/us/stocks/jazz) $14.6 billion

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [Arxis, Inc.](https://www.sectoralpha.in/us/stocks/arxs) $21.8 billion · Electrical Equipment & Parts
2. [NiSource Inc.](https://www.sectoralpha.in/us/stocks/ni) $21.7 billion · Utilities - Regulated Gas
3. Alnylam Pharmaceuticals, Inc. $21.6 billion
4. [Broadridge Financial Solutions, Inc.](https://www.sectoralpha.in/us/stocks/br) $21.4 billion · Information Technology Services
5. [Best Buy Co., Inc.](https://www.sectoralpha.in/us/stocks/bby) $21.3 billion · Specialty Retail

## What else do people ask about Alnylam Pharmaceuticals? ### What is Alnylam Pharmaceuticals's stock price today? Alnylam Pharmaceuticals, Inc.'s stock price is $156.51, −64.6% over the past year. The whole company is worth $21.0 B on the market. It is at its lowest price of the past 52 weeks (range $157 to $458), 44.4% below its 200-day average. The price has been falling for 17 weeks (as of 5 November 2026). ### What were Alnylam Pharmaceuticals's latest quarterly results? Alnylam Pharmaceuticals, Inc. reported revenue of $1.3 B and net profit of $164 M for the Jun 2026 quarter. Earnings per share were $1.21. The operating margin was 17.9%, 20.0 percentage points higher than a year earlier (as of 5 November 2026). ### What is Alnylam Pharmaceuticals's market cap? Alnylam Pharmaceuticals, Inc.'s market capitalisation is $21.0 B at a stock price of $156.51. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 5 November 2026). ### How is Alnylam Pharmaceuticals performing? Alnylam Pharmaceuticals, Inc.'s share price has been falling for 17 weeks. Over the past 13 weeks it has done worse than the S&P 500, for 53 weeks running. This describes what the data did, not a rating (as of 5 November 2026). ### Will Alnylam Pharmaceuticals's stock price go up? This page does not forecast Alnylam Pharmaceuticals, Inc.'s stock price. What it shows instead: the stock price is $156.51, and it has been falling for 17 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 5 November 2026). ### Does Alnylam Pharmaceuticals have too much debt? Alnylam Pharmaceuticals, Inc. has a moderate amount of debt: its debt is 0.83× its equity. A year-by-year history of its borrowings is not in our data, so this uses the latest reading. Keep that borrowing in mind when reading the returns on this page (as of 5 November 2026). ### Where is Alnylam Pharmaceuticals in its business cycle? Alnylam Pharmaceuticals, Inc.'s FY25 operating margin was 13.5%, against a 5-year range of −83.9% to 13.5%: the top of its range, a record year. When profit is at a record, every ratio looks better than usual, and the story depends on margins staying high. The latest quarter was 17.9%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 5 November 2026). ### What could break the Alnylam Pharmaceuticals story? Biggest thing to watch: margins are the best this company has ever reported. Every ratio looks better at a record, so the story depends on margins staying high. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 5 November 2026). ### Is Alnylam Pharmaceuticals a stock worth studying right now? What the numbers show: Alnylam Pharmaceuticals, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 5 November 2026). ## Lists

- Nasdaq 100 companies: https://www.sectoralpha.in/nasdaq-100-stocks

This is research, not advice. We’re not SEBI-registered.